Lonza and California Peptide Research Form Strategic Alliance

CPRI’s high-quality small-scale services complement Lonza's extensive capabilities in custom cGMP peptide manufacturing and development. With proximity to a core customer base in the North American pharmaceutical market, CPRI adds geographic diversity to Lonza's existing facilities in Braine-l'Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kouøim (Czech Republic). CPRI’s offering includes milligram- to multi-gram- scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support.

The alliance will provide customers a more complete peptide offering – from research through commercial supply – and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities. Joint customers will benefit from aligned interfaces and more efficient technology transfer, thereby saving time and costs.

CPRI was identified as a competent innovator and qualified as a Lonza-trusted partner following a diligent selection and auditing process.


Contact:
Lonza Group Ltd Head of Corporate Communications Dominik Werner T.: +41 61 316 8798 F.: +41 61 316 9798 E.: dominik.werner@lonza.com

Lonza Group Ltd Investor Relations Dirk Oehlers T.: +41 61 316 8540 F.: +41 61 316 9540 E.: dirk.oehlers@lonza.com